Wnt signaling in bone and muscle

Bone

Volumn 80, Issue , 2015, Pages 60-66

  Rudnicki, Michael A ^a,b   Williams, Bart O ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Bone; Frizzled; Muscle; Osteoblasts; Satellite stem cells; Wnt

Indexed keywords

LITHIUM CHLORIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; WNT7A;

BONE DEVELOPMENT; CELLULAR SECRETION; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DUCHENNE MUSCULAR DYSTROPHY; FRACTURE HEALING; HOMEOSTASIS; HUMAN; MUSCLE DEVELOPMENT; MUSCLE GROWTH; MUSCLE REGENERATION; MUSCULOSKELETAL DEVELOPMENT; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; WNT SIGNALING PATHWAY; ANIMAL; BONE; CYTOLOGY; GENETICS; METABOLISM; OSTEOBLAST; PHYSIOLOGY;

ANIMALS; BONE AND BONES; HUMANS; MUSCLE, SKELETAL; OSTEOBLASTS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84943641791     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.02.009     Document Type: Review

References (108)

1. Nusse R., Varmus H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31:99-109.
2. Willert K., Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol 2012, 4:a007864.
3. Rijsewijk F., Schuermann M., Wagenaar E., Parren P., Weigel D., Nusse R. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 50:649-657.
4. Gonsalves F.C., DasGupta R. Function of the wingless signaling pathway in Drosophila. Methods Mol Biol 2008, 469:115-125.
5. Nusse R., Brown A., Papkoff J., Scambler P., Shackleford G., McMahon A., et al. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 1991, 64:231.
6. Ke J., Xu H.E., Williams B.O. Lipid modification in Wnt structure and function. Curr Opin Lipidol 2013, 24:129-133.
7. Joiner D.M., Ke J., Zhong Z., Xu H.E., Williams B.O. LRP5 and LRP6 in development and disease. Trends Endocrinol Metab 2013, 24:31-39.
8. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
9. Veeman M.T., Axelrod J.D., Moon R.T. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003, 5:367-377.
10. Singh J., Mlodzik M. Planar cell polarity signaling: coordination of cellular orientation across tissues. Wiley Interdiscip Rev Dev Biol 2012, 1:479-499.
11. Gao B., Yang Y. Planar cell polarity in vertebrate limb morphogenesis. Curr Opin Genet Dev 2013, 23:438-444.
12. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000, 16:279-283.
13. Chen A.E., Ginty D.D., Fan C.M. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005, 433:317-322.
14. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
15. von Maltzahn J., Bentzinger C.F., Rudnicki M.A. Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol 2012, 14:186-191.
16. Surana R., Sikka S., Cai W., Shin E.M., Warrier S.R., Tan H.J., et al. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta 1845, 2014:53-65.
17. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006, 25:7469-7481.
18. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013, 19:179-192.
19. Chang M.K., Kramer I., Huber T., Kinzel B., Guth-Gundel S., Leupin O., et al. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A 2014, 111(48):E5187-E5195.
20. Kadowaki T., Wilder E., Klingensmith J., Zachary K., Perrimon N. The segment polarity gene porcupine encodes a putative multitransmembrane protein involved in Wingless processing. Genes Dev 1996, 10:3116-3128.
21. Takada R., Satomi Y., Kurata T., Ueno N., Norioka S., Kondoh H., et al. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 2006, 11:791-801.
22. Ching W., Nusse R. A dedicated Wnt secretion factor. Cell 2006, 125:432-433.
23. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
24. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-1521.
25. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
26. Ai M., Holmen S.L., Van Hul W., Williams B.O., Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 2005, 25:4946-4955.
27. Balemans W., Devogelaer J.P., Cleiren E., Piters E., Caussin E., Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007, 22:708-716.
28. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 2008, 82:445-453.
29. Semenov M.V., He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 2006, 281:38276-38284.
30. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006, 21:1738-1749.
31. Hsieh J.C., Lee L., Zhang L., Wefer S., Brown K., DeRossi C., et al. MeSD encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell 2003, 112:355-367.
32. Zhang Y., Wang Y., Li X., Zhang J., Mao J., Li Z., et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with MeSD. Mol Cell Biol 2004, 24:4677-4684.
33. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003, 72:763-771.
34. Johnson M.L., Summerfield D.T. Parameters of LRP5 from a structural and molecular perspective. Crit Rev Eukaryot Gene Expr 2005, 15:229-242.
35. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314.
36. Holmen S.L., Giambernardi T.A., Zylstra C.R., Buckner-Berghuis B.D., Resau J.H., Hess J.F., et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004, 19:2033-2040.
37. Iwaniec U.T., Wronski T.J., Liu J., Rivera M.F., Arzaga R.R., Hansen G., et al. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 2007, 22:394-402.
38. Akhter M.P., Wells D.J., Short S.J., Cullen D.M., Johnson M.L., Haynatzki G.R., et al. Bone biomechanical properties in LRP5 mutant mice. Bone 2004, 35:162-169.
39. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
40. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005, 280:21162-21168.
41. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30:3071-3085.
42. Maeda K., Kobayashi Y., Udagawa N., Uehara S., Ishihara A., Mizoguchi T., et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012, 18:405-412.
43. Wei W., Zeve D., Suh J.M., Wang X., Du Y., Zerwekh J.E., et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 2011, 31:4706-4719.
44. Riddle R.C., Diegel C.R., Leslie J.M., Van Koevering K.K., Faugere M.C., Clemens T.L., et al. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One 2013, 8:e63323.
45. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
46. Cui Y., Niziolek P.J., MacDonald B.T., Alenina N., Matthes S., Jacobsen C.M., et al. Reply to Lrp5 regulation of bone mass and gut serotonin synthesis. Nat Med 2014, 20:1229-1230.
47. Kode A., Obri A., Paone R., Kousteni S., Ducy P., Karsenty G. Lrp5 regulation of bone mass and serotonin synthesis in the gut. Nat Med 2014, 20:1228-1229.
48. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.
49. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005, 8:727-738.
50. Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005, 132:49-60.
51. Joeng K.S., Schumacher C.A., Zylstra-Diegel C.R., Long F., Williams B.O. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. Dev Biol 2011, 359:222-229.
52. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39:91-97.
53. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002, 110:144-152.
54. MacDonald B.T., Joiner D.M., Oyserman S.M., Sharma P., Goldstein S.A., He X., et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007, 41:331-339.
55. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.H., Richards J.B., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41:1199-1206.
56. Wan Y., Lu C., Cao J., Zhou R., Yao Y., Yu J., et al. Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells. Bone 2013, 55:258-267.
57. Maruyama T., Jiang M., Hsu W. Gpr177, a novel locus for bone mineral density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal development. J Bone Miner Res 2013, 28:1150-1159.
58. Zhong Z., Zylstra-Diegel C.R., Schumacher C.A., Baker J.J., Carpenter A.C., Rao S., et al. Wntless functions in mature osteoblasts to regulate bone mass. Proc Natl Acad Sci U S A 2012, 109:E2197-E2204.
59. Laine C.M., Joeng K.S., Campeau P.M., Kiviranta R., Tarkkonen K., Grover M., et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013, 368:1809-1816.
60. Keupp K., Beleggia F., Kayserili H., Barnes A.M., Steiner M., Semler O., et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 2013, 92:565-574.
61. Fahiminiya S., Majewski J., Mort J., Moffatt P., Glorieux F.H., Rauch F. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet 2013, 50:345-348.
62. Heilmann A., Schinke T., Bindl R., Wehner T., Rapp A., Haffner-Luntzer M., et al. The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS One 2013, 8:e84232.
63. Albers J., Schulze J., Beil F.T., Gebauer M., Baranowsky A., Keller J., et al. Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol 2011, 192:1057-1072.
64. Tu X., Joeng K.S., Nakayama K.I., Nakayama K., Rajagopal J., Carroll T.J., et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 2007, 12:113-127.
65. Buckingham M., Vincent S.D. Distinct and dynamic myogenic populations in the vertebrate embryo. Curr Opin Genet Dev 2009, 19:444-453.
66. Cossu G., Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J 1999, 18:6867-6872.
67. von Maltzahn J., Chang N.C., Bentzinger C.F., Rudnicki M.A. Wnt signaling in myogenesis. Trends Cell Biol 2012, 22:602-609.
68. Abu-Elmagd M., Robson L., Sweetman D., Hadley J., Francis-West P., Munsterberg A. Wnt/Lef1 signaling acts via Pitx2 to regulate somite myogenesis. Dev Biol 2010, 337:211-219.
69. Tajbakhsh S., Borello U., Vivarelli E., Kelly R., Papkoff J., Duprez D., et al. Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5. Development 1998, 125:4155-4162.
70. Borello U., Berarducci B., Murphy P., Bajard L., Buffa V., Piccolo S., et al. The Wnt/beta-catenin pathway regulates Gli-mediated Myf5 expression during somitogenesis. Development 2006, 133:3723-3732.
71. Ikeya M., Takada S. Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development 1998, 125:4969-4976.
72. Otto A., Schmidt C., Patel K. Pax3 and Pax7 expression and regulation in the avian embryo. Anat Embryol (Berl) 2006, 211:293-310.
73. Aoki K., Taketo M.M. Tissue-specific transgenic, conditional knockout and knock-in mice of genes in the canonical Wnt signaling pathway. Methods Mol Biol 2008, 468:307-331.
74. van Amerongen R., Berns A. Knockout mouse models to study Wnt signal transduction. Trends Genet 2006, 22:678-689.
75. Otto A., Schmidt C., Luke G., Allen S., Valasek P., Muntoni F., et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. J Cell Sci 2008, 121:2939-2950.
76. Murphy M.M., Keefe A.C., Lawson J.A., Flygare S.D., Yandell M., Kardon G. Transiently active Wnt/beta-catenin signaling is not required but must be silenced for stem cell function during muscle regeneration. Stem Cell Rep 2014, 3:475-488.
77. Brack A.S., Conboy M.J., Roy S., Lee M., Kuo C.J., Keller C., et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007, 317:807-810.
78. Schiaffino S., Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev 2011, 91:1447-1531.
79. Anakwe K., Robson L., Hadley J., Buxton P., Church V., Allen S., et al. Wnt signalling regulates myogenic differentiation in the developing avian wing. Development 2003, 130:3503-3514.
80. Takata H., Terada K., Oka H., Sunada Y., Moriguchi T., Nohno T. Involvement of Wnt4 signaling during myogenic proliferation and differentiation of skeletal muscle. Dev Dyn 2007, 236:2800-2807.
81. Tee J.M., van Rooijen C., Boonen R., Zivkovic D. Regulation of slow and fast muscle myofibrillogenesis by Wnt/beta-catenin and myostatin signaling. PLoS One 2009, 4:e5880.
82. Hutcheson D.A., Zhao J., Merrell A., Haldar M., Kardon G. Embryonic and fetal limb myogenic cells are derived from developmentally distinct progenitors and have different requirements for beta-catenin. Genes Dev 2009, 23:997-1013.
83. Charge S.B., Rudnicki M.A. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238.
84. Kuang S., Kuroda K., Le Grand F., Rudnicki M.A. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell 2007, 129:999-1010.
85. Wang Y.X., Rudnicki M.A. Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol 2011, 13:127-133.
86. Le Grand F., Jones A.E., Seale V., Scime A., Rudnicki M.A. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell 2009, 4:535-547.
87. Bentzinger C.F., Wang Y.X., von Maltzahn J., Soleimani V.D., Yin H., Rudnicki M.A. Fibronectin regulates Wnt7a signaling and satellite cell expansion. Cell Stem Cell 2013, 12:75-87.
88. Bentzinger C.F., von Maltzahn J., Dumont N.A., Stark D.A., Wang Y.X., Nhan K., et al. Wnt7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength. J Cell Biol 2014, 205(1):97-111.
89. von Maltzahn J., Renaud J.M., Parise G., Rudnicki M.A. Wnt7a treatment ameliorates muscular dystrophy. Proc Natl Acad Sci U S A 2012, 109:20614-20619.
90. Emery A.E. The muscular dystrophies. BMJ 1998, 317:991-995.
91. Rey J.P., Ellies D.L. Wnt modulators in the biotech pipeline. Dev Dyn 2010, 239:102-114.
92. Lum L., Clevers H. Cell biology. The unusual case of Porcupine. Science 2012, 337:922-923.
93. Mason J.J., Williams B.O. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos 2010, 2010.
94. Gong Y., Bourhis E., Chiu C., Stawicki S., DeAlmeida V.I., Liu B.Y., et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010, 5:e12682.
95. Ettenberg S.A., Charlat O., Daley M.P., Liu S., Vincent K.J., Stuart D.D., et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci U S A 2010, 107:15473-15478.
96. Minear S., Leucht P., Jiang J., Liu B., Zeng A., Fuerer C., et al. Wnt proteins promote bone regeneration. Sci Transl Med 2010, 2:29ra30.
97. Zhao L., Rooker S.M., Morrell N., Leucht P., Simanovskii D., Helms J.A. Controlling the in vivo activity of Wnt liposomes. Methods Enzymol 2009, 465:331-347.
98. Morrell N.T., Leucht P., Zhao L., Kim J.B., ten Berge D., Ponnusamy K., et al. Liposomal packaging generates Wnt protein with in vivo biological activity. PLoS One 2008, 3:e2930.
99. Hedgepeth C.M., Conrad L.J., Zhang J., Huang H.C., Lee V.M., Klein P.S. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997, 185:82-91.
100. Chen Y., Alman B.A. Wnt pathway, an essential role in bone regeneration. J Cell Biochem 2009, 106:353-362.
101. Silkstone D., Hong H., Alman B.A. Beta-catenin in the race to fracture repair: in it to Wnt. Nat Clin Pract Rheumatol 2008, 4:413-419.
102. Janda C.Y., Waghray D., Levin A.M., Thomas C., Garcia K.C. Structural basis of Wnt recognition by Frizzled. Science 2012, 337:59-64.
103. von Maltzahn J., Zinoviev R., Chang N.C., Bentzinger C.F., Rudnicki M.A. A truncated Wnt7a retains full biological activity in skeletal muscle. Nat Commun 2013, 4:2869.
104. Bonewald L.F., Kiel D.P., Clemens T.L., Esser K., Orwoll E.S., O'Keefe R.J., et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2013, 28:1857-1865.
105. Jahn K., Lara-Castillo N., Brotto L., Mo C.L., Johnson M.L., Brotto M., et al. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cell Mater 2012, 24:197-209. [discussion 209-10].
106. Bentzinger C.F., von Maltzahn J., Dumont N.A., Stark D.A., Wang Y.X., Nhan K., et al. Wnt7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength. J Cell Biol 2014, 205:97-111.
107. Cui Y., Niziolek P.J., MacDonald B.T., Alenina N., Matthes S., Jacobsen C.M., et al. Reply to Lrp5 regulation of bone mass and gut serotonin synthesis. Nat Med 2014, 20(11):1229-1230.
108. Kuroda K., Kuang S., Taketo M.M., Rudnicki M.A. Canonical Wnt signaling induces BMP-4 to specify slow myofibrogenesis of fetal myoblasts. Skelet Muscle 2013, 3(1):5.